scholarly journals Molecular cloning and characterization of glucose transporter 1 (glut1) and citrate synthase cDNA in buffalo (Bubalus bubalis)

2013 ◽  
Vol 12 (48) ◽  
pp. 6695-6703
Author(s):  
Nath Amar ◽  
Sharma Veena ◽  
E. Gade Nitin ◽  
M. D. Pratheesh ◽  
Taru Sharma G.
Author(s):  
Kanisht Batra ◽  
Trilok Nanda ◽  
Aman Kumar ◽  
Akhil Kumar Gupta ◽  
Rajni Kumari ◽  
...  

NANO ◽  
2018 ◽  
Vol 13 (01) ◽  
pp. 1850008 ◽  
Author(s):  
Linhui Wang ◽  
Yi Zhao ◽  
Runxin Lu ◽  
Yao Peng ◽  
Li Guo ◽  
...  

Magnetic targeting, which utilizes a magnetic field to specifically deliver therapeutic agents to the targeted regions, can greatly improve the treatment efficiency. Herein, ibuprofen-loaded brain targeting magnetic nanoparticles (AA-Ibu-PEG-DA@MNPs) modified with ascorbic acid (AA) for central nervous system (CNS) drug delivery was designed and synthesized in order to effectively deliver ibuprofen to the brain through Na[Formula: see text]-dependent vitamin C transporter 2 (SVCT2) and glucose transporter 1 (GLUT1). The brain targeting magnetic nanoparticles, AA-Ibu-PEG-DA@MNPs, have a particle size of 82.5[Formula: see text]nm, 2% drug loading capacity and limited cytotoxicity against bEnd.3 cells. What’s more, the nanoparticles maintained the magnetic property with a saturation magnetization level at 52.17[Formula: see text]emu/g and could release ibuprofen when incubated in different mediums, including various buffers, mice plasma and brain homogenate. The results indicate that the magnetic nanoparticles may have the potential to be a promising approach to selectively deliver drugs into the brain. This study may be conducive to the field of CNS drugs delivery.


2015 ◽  
Vol 115 (1) ◽  
pp. 347-354 ◽  
Author(s):  
Seong Kyu Ahn ◽  
Pyo Yun Cho ◽  
Byoung-Kuk Na ◽  
Sung-Jong Hong ◽  
Ho-Woo Nam ◽  
...  

2010 ◽  
Vol 165 (2) ◽  
pp. 293-303 ◽  
Author(s):  
Olga Hrytsenko ◽  
Bill Pohajdak ◽  
Bao-You Xu ◽  
Carol Morrison ◽  
Brenna vanTol ◽  
...  

Nature ◽  
1989 ◽  
Vol 338 (6210) ◽  
pp. 83-87 ◽  
Author(s):  
David E. James ◽  
Marilyn Strube ◽  
Mike Muecdler

2002 ◽  
Vol 368 (3) ◽  
pp. 923-929 ◽  
Author(s):  
Thierry JOËT ◽  
Lennart HOLTERMAN ◽  
Timothy T. STEDMAN ◽  
Clemens H.M. KOCKEN ◽  
Annemarie van der WEL ◽  
...  

Chemotherapy of apicomplexan parasites is limited by emerging drug resistance or lack of novel targets. PfHT1, the Plasmodium falciparum hexose transporter 1, is a promising new drug target because asexual-stage malarial parasites depend wholly on glucose for energy. We have performed a comparative functional characterization of PfHT1 and hexose transporters of the simian malarial parasite P. knowlesi (PkHT1), the rodent parasite P. yoelii (PyHT1) and the human apicomplexan parasite Toxoplasma gondii (T. gondii glucose transporter 1, TgGT1). PkHT1 and PyHT1 share >70% amino acid identity with PfHT1, while TgGT1 is more divergent (37.2% identity). All transporters mediate uptake of d-glucose and d-fructose. PyHT1 has an affinity for glucose (Km0.12mM) that is higher than that for PkHT1 (Km0.67mM) or PfHT1 (Km1mM). TgGT1 is highly temperature dependent (the Q10 value, the fold change in activity for a 10°C change in temperature, was >7) compared with Plasmodium transporters (Q10, 1.5—2.5), and overall has the highest affinity for glucose (Km30μM). Using active analogues in competition for glucose uptake, experiments show that hydroxyl groups at the C-3, C-4 and C-6 positions are important in interacting with PkHT1, PyHT1 and TgGT1. This study defines models useful to study the biology of apicomplexan hexose permeation pathways, as well as contributing to drug development.


Sign in / Sign up

Export Citation Format

Share Document